NCT03798509View on ClinicalTrials.gov

Human CD19 Targeted T Cells Injection Therapy for Relapsed and Refractory CD19-positive Leukemia

PHASE1UnknownINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

March 13, 2019

Primary Completion Date

January 31, 2022

Study Completion Date

January 31, 2024

Conditions
CD19-positiveAcute Lymphoblastic Leukemia
Interventions
DRUG

Human CD19 targeted T Cells Injection

Autologous genetically modified anti-CD19 CAR transduced T cells

Trial Locations (1)

200080

RECRUITING

Shanghai General Hospital, Shanghai

Sponsors
All Listed Sponsors
collaborator

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

OTHER

lead

Hrain Biotechnology Co., Ltd.

INDUSTRY